What is the history of Small Fiber Neuropathy?

Small fiber neuropathy (SFN) was first formally characterized in 1990 by Dr. McArthur and colleagues, who identified it as a distinct condition affecting the small, unmyelinated nerve fibers responsible for pain and autonomic function. While historically dismissed as "idiopathic" or psychosomatic due to normal results on traditional nerve conduction studies, advancements in skin biopsy techniques have since revolutionized our ability to objectively diagnose Small fiber neuropathy.

When and how was Small fiber neuropathy first described?

Before the late 20th century, clinicians struggled to categorize patients who presented with severe burning pain, sensory disturbances, and autonomic dysfunction despite having entirely normal EMG and nerve conduction studies. These tests were designed only to measure large-diameter, myelinated nerve fibers. In 1990, a landmark study published in Neurology by Dr. Justin McArthur and his team formally defined Small fiber neuropathy as a unique clinical entity. By utilizing specialized immunohistochemical staining of skin biopsies, researchers were finally able to visualize and quantify the density of intraepidermal nerve fibers, providing the first objective "gold standard" for diagnosis.

How has our understanding of Small fiber neuropathy evolved?

The understanding of Small fiber neuropathy has shifted from viewing it as a "diagnosis of exclusion" to a recognized, multi-faceted pathology. Initially, it was believed to be primarily associated with diabetes. However, modern research has identified a vast array of triggers, including autoimmune disorders, metabolic conditions, toxic exposures, and channelopathies. Today, we recognize that Small fiber neuropathy is often a symptom of an underlying systemic process rather than a standalone disease, necessitating a comprehensive search for the root cause in every patient.

What historical misconceptions were corrected?

For decades, patients suffering from the excruciating, invisible pain of Small fiber neuropathy were frequently misdiagnosed with psychiatric conditions or fibromyalgia. Because physical examinations were often normal and standard neurological tests showed no damage, patients were told their pain was "all in their head." The development of the skin biopsy and the subsequent validation of the quantitative sensory testing (QST) and autonomic reflex screening tests (ART) finally provided the physical evidence needed to validate the patient experience and correct these historical misconceptions.

How have modern genetics and technology changed diagnosis?

Technological and genetic advancements have significantly increased our diagnostic yield for Small fiber neuropathy. We now understand that genetic mutations, particularly in sodium channel genes such as SCN9A, SCN10A, and SCN11A, can cause hereditary forms of the condition. Key milestones in the evolution of managing this condition include:

• 1990: Formal clinical characterization of Small fiber neuropathy by McArthur et al.


• 1990s-2000s: Standardized use of punch skin biopsies to count intraepidermal nerve fiber density (IENFD).


• 2012: The identification of sodium channelopathy mutations as a primary cause in many idiopathic cases.


• Present: Growing use of corneal confocal microscopy as a non-invasive tool to visualize nerve damage in the eye, which correlates with systemic nerve fiber loss.

How has patient advocacy shaped the field?

Patient advocacy has been instrumental in moving Small fiber neuropathy from a medical mystery into a focus of clinical research. Communities like the 209 members on DiseaseMaps.org have provided a collective voice, pushing for greater physician awareness and the funding of clinical trials. By sharing their lived experiences, patients have helped researchers identify common comorbidities—such as POTS (Postural Orthostatic Tachycardia Syndrome) and Ehlers-Danlos Syndrome—that frequently overlap with Small fiber neuropathy.

Next steps

• Consult with a board-certified neurologist or a peripheral nerve specialist to review your sensory symptoms.


• Request a skin biopsy for intraepidermal nerve fiber density (IENFD) testing if you suspect Small fiber neuropathy.


• Join the DiseaseMaps.org community to connect with others and track your symptoms alongside 209 other members.


• Discuss potential genetic testing for channelopathies with a genetic counselor if you have a strong family history of unexplained neuropathic pain.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases (GARD) Information Center: Small Fiber Neuropathy overview.


• Orphanet: Rare disease database entry for peripheral neuropathy.


• OMIM (Online Mendelian Inheritance in Man): Database on SCN9A-related painful neuropathy.


• The Neuropathy Association (Foundation for Peripheral Neuropathy): Clinical guidelines and patient resources.